0
Lung Cancer: Lung Cancer III |

The Role of NY-ESO-1 Activated Dendritic Cell Vaccines in Treating Advanced Non-small Cell Lung Cancer FREE TO VIEW

Yu Dan; Jianli Tang; Qiasheng Li; Huanhuan Zhang; Chengzhi Zhou; Runhui Zheng; Jun Xu
Author and Funding Information

State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A313. doi:10.1016/j.chest.2016.02.326
Text Size: A A A
Published online

SESSION TITLE: Lung Cancer III

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Immunotherapy is emerging as a major modality in treating non-small cell lung cancer (NSCLC) that is not sensitive to traditional anti-cancer therapies. Because of poor immunogenicity and heterogeneity of NSCLC, there is no international recognition of the DC vaccine. NY-ESO-1 is one of the most potential antigens within all testicular Cancer antigens and because of epitope spreading, vaccines against NY-ESO1 may also lead to a development of immune responses against other antigens. So our study is aimed to develop a new model of clinical immunotherapy with NY-ESO-1 sensitized DC vaccines.

METHODS: Peripheral blood mononuclear cells (PBMC) from HLA-A0201 or HLA-A2402 positive NSCLC patients were assayed with an NYESO-1 peptide-specific pentamer. Those with more than 0.01% NYESO-1 pentamer positive CD8+ T cells in lymphocyte was selected as DC vaccine groups and received DC vaccines once a week for four consecutive weeks at 1 months after chemotherapy and radiotherapy. By ELISPOT, flow cytomety, NY-ESO-1 specific T cells, NK cells, Tregs were detected before and after vaccine treatment, and the progression free survival (PFS) was compared in DC and control groups.

RESULTS: In comparison with pre-treatment, IFN-r-producing NYESO-1-specific T cells, NK cells and CD56 dim subsets of NK cells were increased in peripheral blood of NSCLC patients at one week after the first vaccine treatment but without change after the second or third DC vaccine treatment. Tregs’ ratio of peripheral blood cells were not significantly different before and after treatment in NSCLC patients. PFS in patients of DC groups were more than control groups (9.42 months vs 7.30 months). The over all survival time of DC groups takes longer to observe but already above 18.62±7.44 months so far.

CONCLUSIONS: NY-ESO-1 antigen peptide sensitized DC vaccines can induce antigen specific cytotoxic T cells, the NK subgroup with cytotoxic effect, prolong PFS of NSCLC patients, but can't change the level of Tregs in NSCLC patients.

CLINICAL IMPLICATIONS: NY-ESO-1 antigen peptide sensitized DC can effectively induce the anti-tumor immune response in NSCLC patients. This may be a promising treatment combined with chemotherapy and radiotherapy against advanced NSCLC in the future.

DISCLOSURE: The following authors have nothing to disclose: Yu Dan, Jianli Tang, Qiasheng Li, Huanhuan Zhang, Chengzhi Zhou, Runhui Zheng, Jun Xu

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543